drugset / Trial / NCT05926440
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the immunogenicity and safety of SCB-2023 trivalent vaccine compared to the prototype SCB-2019 monovalent vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19 vaccine ≥6 months prior to enrollment.
Timeline
- Start
- 2023-08-17
- Primary completion
- 2023-08-17
- Completion
- 2023-08-17
Outcome
Outcome not reported
Stopped: “we has selected a new candidate vaccine which is monovalent.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SCB-2019 | Vaccine | — | Intramuscular |
| Subject | SCB-2023 | Vaccine | — | Intramuscular |